The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet

TAVR vs. surgery, FFR-guided PCI and DCB safety: Day 3 at ACC.22

Read our in-person coverage of the final day of ACC.22.

Steven E. Nissen, MD, discusses his late-breaking clinical trial with panelist Vera Bittner, MD.

Cholesterol medications, flu shots and heart failure: Day 2 at ACC.22

Day 2 of ACC.22 was jam-packed with late-breaking clinical trials. Read our quick rundown of what researchers shared with the public for the very first time. 

Cardiology groups debut new heart failure guidelines ahead of ACC.22

The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.

Depression linked to a higher stroke risk among heart attack survivors

The new findings, based on data from nearly 500,000 patients, were presented during ACC.22.

Women less likely to receive treatment, more likely to die after cardiogenic shock

Emerging data about differences in treatment for women and men may shed light on diverging outcomes.

Thumbnail

ACC health policy statement calls out negative work environments in cardiology

The statement offers resources and tools to combat bias, discrimination, bullying, and harrassment.